170 related articles for article (PubMed ID: 25277422)
1. [Evaluation of transfusion hemochromatosis prevalence, SFVTT-01 study: preliminary results of the SFVTT working group].
Leo-Kodeli S; Renaudier P; Lassale B
Transfus Clin Biol; 2014 Nov; 21(4-5):182-8. PubMed ID: 25277422
[TBL] [Abstract][Full Text] [Related]
2. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload--the RELATH study.
Lobo C; Angulo IL; Aparicio LR; Drelichman GI; Zanichelli MA; Cancado R;
Hematology; 2011 Sep; 16(5):265-73. PubMed ID: 21902889
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
4. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
Du Y; Long Z; Chen M; Han B; Hou B; Feng F
Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).
Vichinsky E; El-Beshlawy A; Al Zoebie A; Kamdem A; Koussa S; Chotsampancharoen T; Bruederle A; Gilotti G; Han J; Elalfy M
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28296163
[TBL] [Abstract][Full Text] [Related]
6. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
7. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
8. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
[TBL] [Abstract][Full Text] [Related]
9. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
[TBL] [Abstract][Full Text] [Related]
10. Transfusional iron overload in patients with myelodysplastic syndromes: A 10-year retrospective survey from a French general hospital.
Bauduer F; Recanzone H
Transfus Clin Biol; 2020 Aug; 27(3):128-132. PubMed ID: 32561328
[TBL] [Abstract][Full Text] [Related]
11. [Determinants for iron overload in patients with acute leukemias and aplastic anemia].
Makeshova AB; Levina AA; Mamukova IuI; Tsibul'skaia MM; Makarova PM; Romanova EA; Fevraleva IS; Sudarikov AB; Golovkina LL; Stremoukhova AG; Parovichnikova EN; Savchenko VG
Ter Arkh; 2010; 82(7):26-9. PubMed ID: 20853605
[TBL] [Abstract][Full Text] [Related]
12. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
[TBL] [Abstract][Full Text] [Related]
14. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
17. Screening for hemosiderosis in patients receiving multiple red blood cell transfusions.
de Jongh AD; van Beers EJ; de Vooght KMK; Schutgens REG
Eur J Haematol; 2017 May; 98(5):478-484. PubMed ID: 28129458
[TBL] [Abstract][Full Text] [Related]
18. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
[TBL] [Abstract][Full Text] [Related]
19. Iron chelation with deferasirox for the treatment of secondary hemosiderosis in pediatric oncology patients: a single-center experience.
Ktena YP; Athanasiadou A; Lambrou G; Adamaki M; Moschovi M
J Pediatr Hematol Oncol; 2013 Aug; 35(6):447-50. PubMed ID: 23669734
[TBL] [Abstract][Full Text] [Related]
20. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
Tsironi M; Polonifi K; Deftereos S; Farmakis D; Andriopoulos P; Moyssakis I; Aessopos A
Eur J Haematol; 2005 Oct; 75(4):355-8. PubMed ID: 16146544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
